<MedlineCitation Status="Completed">
<MedlineID>10011452</MedlineID>
<PMID>33715</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3002</ISSN>
<JournalIssue>
<Volume>566</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>The activity of arylsulfatase A and B on tyrosine O-sulfates.</ArticleTitle>
<Pagination>
<MedlinePgn>321-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>L-Tyrosine O-sulfate was hydrolyzed by pure human arylsulfatase A (arylsufate sulfohydrolase, EC 3.1.6.1). The rate of hydrolysis was 1/20 of the rate with nitrocatechol sulfate, but was comparable to the rate with cerebroside sulfate. The reaction was optimal at pH 5.3--5.5 and displayed zero order kinetics with time and enzyme concentration. The Km was about 35 mM. The enzyme showed no stereospecificity and hydrolyzed D-tyrosine O-sulfate with Km and V similar to those for the L-isomer. Arylsulfatase B was less than 5% as effective as arylsulfatase A in catalyzing the hydrolysis of the tyrosine sulfates. The daily urinary excretion of tyrosine sulfate by a patient with metachromatic leukodystrophy (arylsulfatase A deficiency) was comparable to the excretion by control subjects. The biological relevance of the tyrosine sulfatase activity of arylsulfatase A remains uncertain.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Fluharty</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author>
<LastName>Stevens</LastName>
<ForeName>R L</ForeName>
<Initials>RL</Initials>
</Author>
<Author>
<LastName>Goldstein</LastName>
<ForeName>E B</ForeName>
<Initials>EB</Initials>
</Author>
<Author>
<LastName>Kihara</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Biochim Biophys Acta</MedlineTA>
<NlmUniqueID>0217513</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>55520-40-6</RegistryNumber>
<NameOfSubstance>Tyrosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.6.</RegistryNumber>
<NameOfSubstance>Sulfatases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.6.8</RegistryNumber>
<NameOfSubstance>Cerebroside-Sulfatase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.6.9</RegistryNumber>
<NameOfSubstance>Chondro-4-Sulfatase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Cerebroside-Sulfatase</DescriptorName>
<QualifierName>deficiency</QualifierName>
<QualifierName MajorTopicYN="Y">urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Chondro-4-Sulfatase</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Leukodystrophy, Metachromatic</DescriptorName>
<QualifierName>enzymology</QualifierName>
<QualifierName>urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Placenta</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Substrate Specificity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Sulfatases</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y">urine</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Tyrosine</DescriptorName>
<QualifierName MajorTopicYN="Y">analogs &#38; derivatives</QualifierName>
<QualifierName>metabolism</QualifierName>
<QualifierName>urine</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
